Download Free Sample Report

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs. This report contains market size and forecasts of Adrenoleukodystrophy Drugs in global, including the following market information:
Global Adrenoleukodystrophy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Adrenoleukodystrophy Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Adrenoleukodystrophy Drugs companies in 2022 (%)
The global Adrenoleukodystrophy Drugs market was valued at US$ 347.6 million in 2022 and is projected to reach US$ 936.8 million by 2029, at a CAGR of 15.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
We surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:

• Hormone Replacement
• Transplant
• Others

• Childhood Cerebral ALD
• Adrenomyeloneuropathy (AMN)
• Addison-only
• Others

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

• Key companies Adrenoleukodystrophy Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Adrenoleukodystrophy Drugs revenues share in global market, 2022 (%)
• Key companies Adrenoleukodystrophy Drugs sales in global market, 2018-2023 (Estimated), (K Units)
• Key companies Adrenoleukodystrophy Drugs sales share in global market, 2022 (%)

• Bluebird Bio Inc
• NeuroVia, Inc.
• Orpheris, Inc.
• Minoryx
• MedDay Pharmaceuticals

• Chapter 1: Introduces the definition of Adrenoleukodystrophy Drugs, market overview.
• Chapter 2: Global Adrenoleukodystrophy Drugs market size in revenue and volume.
• Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
• Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
• Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
• Chapter 6: Sales of Adrenoleukodystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
• Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
• Chapter 8: Global Adrenoleukodystrophy Drugs capacity by region & country.
• Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
• Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
• Chapter 11: The main points and conclusions of the report.